Pentoxifylline affects cytokine reaction in cardiopulmonary bypass.
BACKGROUND
Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations.


METHODS
In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points.


RESULTS
TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05).


CONCLUSIONS
Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.
Iskesen
Ihsan
I
Department of Cardiovascular Surgery, Celal Bayar University School of Medicine, Manisa, Turkey. iskesen@yahoo.com
Saribulbul
Osman
O
Cerrahoglu
Mustafa
M
Onur
Ece
E
Destan
Bugra
B
Sirin
Bekir Hayrettin
BH
D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control*; D010431:Pentoxifylline / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D016896:Treatment Outcome
D016207:Cytokines; D010975:Platelet Aggregation Inhibitors; D010431:Pentoxifylline